

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Lindsay Brigitte Ute</u> _____ (Last) (First) (Middle) 11055 FLINTKOTE AVENUE _____ (Street) SAN DIEGO CA 92121 _____ (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 01/27/2026	3. Issuer Name and Ticker or Trading Symbol <u>Cardiff Oncology, Inc. [CRDF]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Accounting Officer</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) _____ 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	27,431	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
Stock Options	(1)	01/23/2028	Common Stock	1,753	21.6	D
Stock Options	(2)	06/20/2029	Common Stock	89,469	2.48	D
Stock Options	(3)	06/17/2030	Common Stock	96,192	2.6	D
Stock Options	(4)	06/10/2031	Common Stock	154,704	7.98	D
Stock Options	(5)	03/09/2032	Common Stock	131,568	2.5	D
Stock Options	(6)	03/15/2033	Common Stock	90,288	1.72	D
Stock Options	(7)	03/17/2034	Common Stock	95,040	3.51	D
Stock Options	(8)	03/11/2035	Common Stock	166,320	3.58	D

Explanation of Responses:

- 1,198 vested on January 23, 2018. 185 vested on January 23, 2019, 2020 and 2021.
- 29,823 vested on June 20, 2020, 2021 and 2022.
- 32,064 vested on June 17, 2021, 2022 and 2023.
- 38,676 vested on June 10, 2022 and 3,223 vested monthly for 36 months thereafter.
- 32,892 vested on March 9, 2023 and 2,741 vest monthly for 36 months thereafter.
- 22,572 vested on March 15, 2024 and 1,881 vest monthly for 36 months thereafter.
- 23,760 vested on March 7, 2025 and 1,980 vest monthly for 36 months thereafter.
- 41,580 vest on March 11, 2026 and 3,465 vest monthly for 36 months thereafter.

/s/ Brigitte Lindsay

02/09/2026

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.